EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy

Mutaz Dwairy iD, Alaa Yehya, Feras M Mohammad, Hiba Alzoubi

PLOS One · 11.07.2025 · 20 (7) · e0328196

DOI: 10.1371/journal.pone.0328196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.07.2025. Verfasst von Mutaz Dwairy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Civil Engineering, Yarmouk University, Irbid, Jordan. Hauptthemen laut MEDLINE: Losartan, Breast Neoplasms, Tumor Microenvironment, Angiotensin II Type 1 Receptor Blockers. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yarmouk University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor stiffness is a critical factor influencing cancer progression, therapeutic resistance, and drug delivery. This study investigates the role of mechanical normalization in breast cancer therapy through the anti-fibrotic action of losartan, an angiotensin II type 1 receptor blocker. We developed a comprehensive multiphysics model integrating tumor cell proliferation, oxygen transport, interstitial fluid dynamics, and losartan pharmacokinetics/pharmacodynamics (PK/PD). Simulations demonstrate that losartan reduces tumor stiffness by up to 28%, enhances oxygenation by 8%, and increases tumor porosity by ~45%, thereby enhancing drug penetration and interstitial transport. Furthermore, tumor cell concentration decreased by 88%, reflecting the drug’s dual anti-proliferative and pro-apoptotic effects. Spatial analyses revealed heterogeneity in stiffness reduction and drug response, emphasizing the importance of tumor geometry and perfusion. Our findings support the potential of losartan as a mechanotherapeutic adjuvant to enhance standard cancer treatments by remodeling the tumor microenvironment and overcoming mechanical barriers to therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LosartanBreast NeoplasmsTumor MicroenvironmentAngiotensin II Type 1 Receptor BlockersHumansFemaleCell ProliferationModels, BiologicalTreatment Outcome

Substanzen

LosartanAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Civil Engineering, Yarmouk University, Irbid, Jordan.
  • Department of Biomedical Systems and Informatics Engineering, Yarmouk University, Irbid, Jordan.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.
  • Faculty of Medicine, Yarmouk University, Irbid, Jordan.
  • Department of Basic Disease Sciences, Pathology Division, Faculty of Medicine, Yarmouk University, Irbid, Jordan.

ORCID-Profile: Mutaz Dwairy

Förderung

  • Yarmouk University

Zitieren

APA

Dwairy, M., Yehya, A., Mohammad, F. M., & Alzoubi, H. (2025). Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy. PLOS One, 20(7), e0328196. https://doi.org/10.1371/journal.pone.0328196

Vancouver

Dwairy M, Yehya A, Mohammad FM, Alzoubi H. Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy. PLOS One. 2025;20(7):e0328196. doi:10.1371/journal.pone.0328196

BibTeX
@article{Dwairy2025,
  author = {Dwairy, Mutaz and Yehya, Alaa and Mohammad, Feras M and Alzoubi, Hiba},
  title = {Losartan as a mechanotherapeutic adjuvant: Remodeling the breast tumor microenvironment to improve treatment efficacy},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {7},
  pages = {e0328196},
  doi = {10.1371/journal.pone.0328196}
}
Kostenlos starten →